



INVEST LIKE A PRO, WITH THE PROS!



See the [new Digest](#) for 10 consumer stocks to profit from strong U.S. consumer confidence including one high-flying company that is disrupting how people shop for clothes.



Keep reading to see why *Tilray* is surging again today.

Please send any comments, questions or concerns about the [new website](#) to:

customercare@capitalideasresearch.com

Morning Need to Know

Getting you ready for your investing day

September 19, 2018

Written & compiled by Mark Bunting, Publisher,
Capital Ideas Media



CANADIAN ANALYSTS' CALLS

INITIATIONS

Vermilion (TSX:VET::NYSE:VET) Raymond James is the latest to get on the Vermilion bandwagon, after our cover story last week and contributor Fabrice Taylor recommending the stock on BNN Bloomberg, setting an "outperform" rating and a target of \$52 (Canadian).

Sangoma Technologies (TSXV:STC) PI Financial

begins coverage of this stock, which we featured in the Digest in May, with a "buy" and a target of \$2.25.

**

Uni-Select (TSX:UNS) RBC reduces its price target to \$22 from \$25, giving the stock 22% upside, and maintains "outperform" after the CEO stepped down, the company reduced its forecast and announced a strategic review. Desjardins downgrades to "buy" and cuts the target to \$29 from \$32.

Conifex (TSX:CFF) CIBC is reducing its EPS estimates and price target projections on a number of paper and forestry companies including CFF, which sees its target cut to \$5.50 from \$9.



U.S. ANALYSTS' CALLS

Constellation Brands (NYSE:STZ) RBC maintains its "outperform" rating and price target of \$300 (U.S.), which indicates a gain of 41%, after conducting its quarterly distributor survey of the beer industry saying investors should:

"...buy on recent weakness"...and that... "the

Canopy Growth investment was the result of a forward looking management team and board of directors, and not deteriorating beer trends."

Discovery (NASDAQ:DISCA) RBC raises the price target to \$38 from \$30, implying 20% gains, and maintains "outperform".

Biocryst Pharma (NASDAQ:BCRX), Intra-Cellular Therapeutics (NASDAQ:ITCI), Immune Design CS (NASDAQ:IMDZ) RBC says these three biotechs could double in the next six-to-12 months based on:

"...underappreciated pipelines, relatively near-term catalysts, and a valuation disconnect we think could enable substantial upside opportunity on favourable developments."

Ericsson (NASDAQ:ERIC) Credit Suisse lifts the target to a very specific \$8.44 from \$7.19 citing the possibility of the company exceeding its 2020 financial targets.

Nike (NYSE:NKE) B. Riley FBR hikes the target to \$84 from \$76.

STOCKS THAT MAY MOVE

Tilray (NASDAQ:TLRY) has surged another 50% as I write this after its CEO told CNBC cannabis is a "great hedge" for alcohol, tobacco and pharmaceutical companies. That's it. That's all he said. And yet it's apparently

enough to send this company with something like just under \$30 million in revenue to a market cap of about \$14.4 billion.

I talked to a very smart hedge fund manager recently with a great track record who said cannabis is a bubble but that bubbles are tricky because you want to ride the bubble or else you leave a ton of money on the table. But you also have to hedge those long bets with some short positions because when the mania ends, and I'm paraphrasing here, it will be ugly.

Tilray is tough to short though because the float is relatively small at 93 million shares and most of them are held by retail investors. The percentage of Tilray shares being shorted is about 34%, according to analytics firm S3 Partners. Point being: be careful out there.

Kirkland Lake Gold (TSX:KL) is buying 14.7 million common shares of **Osisko Mining (TSX:OSK)** through a private placement at \$1.70 per share or about \$25 million. Kirkland Lake now owns 13.6% of Osisko, up from 8.6%.

Eldorado Gold (TSX:ELD) is seeking 750 million euros in damages from Greece it says were incurred caused by delays in getting permits for its Skouries project. Greece's government says the company submitted a deficient plan to build a metallurgical plant.

Sunniva (CSE:SNN) has struck a \$10 million

bought deal financing through a syndicate of underwriters led by Beacon Securities and Canaccord Genuity, which is buying 1.9 million units at \$5.27 per unit.

Alibaba (NYSE:BABA) will set up an artificial intelligence semiconductor subsidiary, and is teaming with SAP to offer the company's products on its cloud infrastructure.

With files from The Globe and Mail, Reuters and Bloomberg News.

MARKETS

TSX and U.S. equity futures are mixed, European stock indices are mostly higher and Asian stock indices overnight were in the black.

CURRENCIES

The Canadian dollar is modestly higher at \$77.12 U.S.

Bitcoin is down by 0.8% to \$6,280, according to CoinDesk.

COMMODITIES

West Texas Intermediate is flat at \$69.65 a barrel (U.S.).

Gold is up 0.6% at \$1,210.10 an ounce.

Daily Update

Create your own portfolio and build a watchlist with the [Portfolio Tracker](#) on our new website. It's a compelling new feature for subscribers to keep track of their investments.

Tackling the "next great frontier" of cannabis – the huge U.S. market. [Listen](#) to our conversation with [Cannex Capital \(CSE:CNNX\)](#) CEO **Anthony Dutton** in our new podcast.

Get 25% off the annual subscription price for the [Capital Ideas Digest](#) by becoming a [premium member](#) and receive immediate access to all of our best research-based insights and ideas.

Peter Hodson and **Ryan Modesto** of **5i Research** are offering a limited time [30-Day Free Trial](#) to get access to all of their independent, conflict-free company reports.

[Capital Ideas TV](#)

Thursdays on YouTube at 7 pm ET, 4 pm PT.

Sundays on BNN Bloomberg at 9 pm ET, 6 pm PT.

[Capital Ideas Digest](#)

Tuesday's at 7 pm ET, 4 pm PT.

[Capital Ideas Radio](#)

Anytime, anywhere.

Access, insight and ideas.

Have a great day!

Mark Bunting
Publisher,
Capital Ideas Media



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[unsubscribe from this list](#) [update subscription preferences](#)

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada